Dr. Yvan Devaux from LIH works on the theme of the Nobel Prize awarded today to two American researchers for their work on microRNAs. He explains the importance of the discovery and his own research....

© Ill. Niklas Elmehed © Nobel Prize Outreach; LIH

Left: The two American Nobel laureates Victor Ambros et Gary Ruvkun; right: Dr. Yvan Devaux from the Luxembourg Institute of Health

The Nobel Prize for Medicine was awarded on Monday 7 October 2024 to Professors Victor Ambros and Gary Ruvkun for their work on microRNAs.

These tiny molecules play a key role in regulating gene expression, i.e. they help to control which genes are activated or deactivated in our cells.  They play a crucial role in regulating many biological processes and even in preventing disease.

Dr Yvan Devaux, from the Luxembourg Institute of Health (LIH), is working on these microRNAs. His aim is to develop new diagnostic and therapeutic methods for heart and brain diseases.

 

Can you sum up today's Nobel Prize in Medicine in a few sentences, and tell us whether it is deserved?

Yvan Devaux: ‘The Nobel Prize for Medicine 2024 was awarded today for research into microRNAs. MicroRNAs are small molecules found everywhere, in our cells and our blood, which regulate the expression of our genes, and therefore the expression of proteins in our bodies.

  • Our cells contain genes which are like instructions for making proteins (the building blocks and machines of our body).
  • To produce a protein from a gene, the cell must first copy the information from the gene into messenger RNA (mRNA), which serves as the blueprint.
  • MicroRNAs interfere with this process: they can bind to certain mRNAs and prevent them from being translated into proteins. It's as if microRNAs were putting on the ‘brakes’ to prevent a protein from being made.

 

MicroRNAs help to regulate the quantity of proteins produced in the cell, playing a key role in many biological processes, such as growth, development and even disease initiation and progression.

Image : The flow of genetic information from DNA to mRNA to proteins. The identical genetic information is stored in DNA of all cells in our bodies. This requires precise regulation of gene activity so that only the correct set of genes is active in each specific cell type. © The Nobel Committee for Physiology or Medicine. Ill. Mattias Karlén

‘The Nobel Prize is, in my view, very deserved, because the discovery of microRNAs has opened up a very broad field of research and applications; at present, thousands of research teams around the world are working hard on them to try to understand how these small molecules are involved in various diseases, such as degenerative diseases (Parkinson's, Alzheimer's) or cardiovascular diseases.

The field is particularly promising because microRNAs can be used to diagnose and treat these diseases, in particular by modulating them with synthetic tools. It is possible to administer small synthetic RNAs to humans that increase or decrease the expression of microRNAs involved in the disease.

And by the way: It’s the third time in past 5 years that a Nobel Prize is awarded to the topic of RNAs, after the discovery of RNA modifications that allowed the development of mRNA vaccines in 2023 (Profs Katalin Karikó and Drew Weissman) and the discovery of RNA editing in 2020 (Profs Jennifer Doudna and Emmanuelle Charpentier). This goes to show the importance of these molecules in biology and medicine.'

Do you have any concrete examples of the application of microRNAs in the field of health?

Yvan Devaux: ‘A few small interfering RNAs are currently approved by health institutions, for example for the treatment of hypercholesterolaemia, which is a major public health problem. Numerous studies are underway into the use of microRNAs for the treatment of various pathologies.

Another area of research is heart failure, also a major health issue: a molecule has been identified by a German team that could reduce the problems associated with heart failure, and is showing very promising results’.

Can you describe the impact of this new field of research on your career?

Yvan Devaux: ‘Before I became director of the cardiovascular research laboratory at the LIH, it was Dr Daniel Wagner, a cardiologist at the CHL (Centre Hospitalier de Luxembourg), who set it up. I remember driving to Maastricht with him in 2008 to see a scientific colleague: it was dark and we were driving through the snow in the Belgian Ardennes. We were about to publish one of the very first studies on microRNAs, which was finally published in 2010 and focused on patients who had suffered a myocardial infarction at the CHL. It is currently one of the most cited studies in the field, so we were among the pioneers of this research.

Unfortunately, Daniel Wagner passed away too early, so a foundation was set up in his honour: the Daniel Wagner Heart Foundation, which funds a large part of our research. The work of this foundation is essential.

Photo: Une partie de l’équipe du laboratoire de recherche cardiovasculaire du LIH (à droite sur la photo : Yvan Devaux) lors de la Journée Mondiale du Cœur, qui a eu lieu samedi 28 septembre dernier Place d’Armes à Luxembourg. Cette journée (World Heart Day) a pour but de sensibiliser le public aux risques cardiovasculaires et à la recherche qui est faite au Luxembourg dans ce domaine.

Photo: Part of the LIH cardiovascular research laboratory team (on the right in the photo: Yvan Devaux) at World Heart Day, which took place on Saturday 28 September at Place d'Armes in Luxembourg. The aim of World Heart Day is to raise public awareness of cardiovascular risks and the research being carried out in Luxembourg in this area. Credit: www.photobooth.lu; Ministry of Health.

How does your research contribute to the specific field of microRNAs?

Yvan Devaux: ‘The LIH is very interested in research into inflammatory and neurodegenerative diseases such as Parkinson's disease. The aim is to identify the microRNAs involved. In fact, I'm in the middle of preparing a presentation on a very specific microRNA, called microRNA-124, which could improve the prognosis after cardiac arrest. In collaboration with the CHL intensive care unit, we have found that this microRNA-124 is released in large quantities by the brain in the event of cerebral damage following cardiac arrest; its presence can be measured using a simple blood test. Knowing this enables us to improve patient treatment by identifying this poor prognostic factor at an early stage and implementing immediate neuroprotective measures.

The presentation will take place during the Translational Medicine Research Day on 16 October at the CHL.

For more information on the Nobel Prize, follow this link to the official press release.

Author: Diane Bertel
Editor: Michele Weber

Auch in dieser Rubrik

Handy in Schule
Screentime Smartphone-Verbot in Schulen: Was ist der Stand der Wissenschaft?

Sollen Sekundarschulen Handys in Klassenraum und Pausenhof verbieten oder nicht? Das diskutieren Eltern, Lehrer, Schüler und Politik in Luxemburg und weltweit. Ein Blick auf den Stand der Forschung.

University of Luxembourg
Demenzerkrankungen Alzheimer: Wo steht die Wissenschaft?

Sie beginnt schleichend und ist bisher nicht heilbar: die Alzheimer-Krankheit. Prof. Dr. Michael Heneka, Direktor des Luxembourg Centre for Systems Biomedicine, über Forschungsstand und Therapien.

LCSB, University of Luxembourg
Sportwissenschaft Wie können Spitzensportler ihre Leistung steigern?

Es geht auch ohne verbotene leistungssteigernde Medikamente – z. B. mit Hitze, Kälte und Höhe. Frédéric Margue erklärt, wie ein Team am LIHPS Spitzensportler aus Luxemburg unterstützt.

Pollen.lu – die App Pollenallergie: Eine luxemburgische App hilft Allergikern

Momentan fliegt Pollen überall durch die Luft – ein großes Problem für Allergiker. Erfahre mehr über Pollen.lu, die luxemburgische App zum besseren Umgang mit Pollenallergie.

LIH, CHL